PB2096: A PHASE 1B/2 STUDY OF GB5121, A NOVEL, HIGHLY SELECTIVE, POTENT, AND CNS-PENETRANT BTK INHIBITOR FOR RELAPSED/REFRACTORY PRIMARY/SECONDARY CNS LYMPHOMA AND PRIMARY VITREORETINAL LYMPHOMA
HemaSphere | June 25, 2022 | Volume: 6 | Issue: No issue available | Pages: 1967-1968
10.1097/01.hs9.0000851216.47783.78